文献速递细菌感染、耐药与抗菌药物

头孢他啶/阿维巴坦联合氨曲南对多重耐药嗜麦芽窄食单胞菌复合群的体外抗菌活性评价

Evaluating the antibacterial activity of ceftazidime/avibactam and aztreonam combinations against multidrug-resistant Stenotrophomonas maltophilia complex isolates in a hollow fibre infection model.
PubMed 文献 · Clin Microbiol Infect · 2026-02-14

该研究采用静态浓度时间杀菌试验、机制性药代动力学/药效学模型及中空纤维感染模型,评估氨曲南联合头孢他啶/阿维巴坦对11株嗜麦芽窄食单胞菌复合群(Smc)的抗菌活性。临床相关暴露下联合方案使菌落计数-时间曲线下面积降低31%–74%,在中空纤维模型中24小时较初始约7.5-log10 CFU/mL接种量实现≥3-log10 CFU/mL下降,对GG6菌株效应持续168小时;对非GG6菌株72小时后出现约2-log10再生长,但总体较甲氧苄啶/磺胺甲噁唑更有效抑制耐药亚群。

要点

  • 氨曲南联合头孢他啶/阿维巴坦对多重耐药Smc分离株具有协同杀菌活性。
  • 中空纤维模型中联合方案24小时实现≥3-log10 CFU/mL下降,对GG6菌株维持至168小时。
  • 非GG6菌株72小时后出现约2-log10再生长,但耐药亚群抑制优于甲氧苄啶/磺胺甲噁唑。

核心结论

  • 氨曲南联合头孢他啶/阿维巴坦对多重耐药Smc显示出治疗潜力,支持进一步在小鼠肺炎和菌血症模型中评估。

研究设计与样本

  • 研究对11株Smc分离株进行静态浓度时间杀菌试验,并建立机制性药代动力学/药效学模型指导方案选择。
  • 所选方案在临床相关药物暴露下于中空纤维感染模型中评估,并通过群体分析谱和扫描电镜评估耐药出现及形态学变化。

主要发现

  • 临床相关氨曲南+头孢他啶/阿维巴坦暴露在静态浓度时间杀菌试验中使所有Smc分离株的对数转化菌落计数-时间曲线下面积降低31%–74%。
  • 中空纤维感染模型中,联合方案在24小时较初始约7.5-log10 CFU/mL接种量实现≥3-log10 CFU/mL下降。
  • 对GG6菌株该效应持续168小时;对非GG6菌株,持续输注和标准给药方案在72小时后均出现约2-log10再生长,但总体较甲氧苄啶/磺胺甲噁唑更有效抑制耐药亚群。

关键数值与推荐

  • 静态浓度时间杀菌试验中联合方案使曲线下面积降低31%–74%。
  • 中空纤维模型中24小时实现≥3-log10 CFU/mL下降,初始接种量约7.5-log10 CFU/mL。
  • 非GG6菌株在72小时后出现约2-log10再生长。

临床怎么用

  • 提示氨曲南联合头孢他啶/阿维巴坦可作为多重耐药Smc感染(如囊性纤维化或免疫抑制患者)的潜在治疗选择,但需进一步体内模型验证。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Stenotrophomonas maltophilia is a multidrug-resistant Gram-negative pathogen causing serious infections in vulnerable populations, including individuals with cystic fibrosis and immunocompromised patients. We evaluated the activity of aztreonam (ATM) and ceftazidime/avibactam (CZA) against S. maltophilia complex (Smc) isolates. METHODS: Interactions between ATM and CZA were evaluated using static concentration time-kill assays across 11 Smc isolates. A mechanism-based pharmacokinetic/pharmacodynamic model was developed to characterize bacterial killing dynamics and guide regimen selection. Selected regimens were then evaluated in the hollow fibre infection model under clinically relevant drug exposures. Emergence of resistance was assessed via population analysis profiles, and scanning electron microscopy visualized antibiotic-induced morphological changes. RESULTS: Clinically relevant ATM + CZA exposures produced 31-74% reduction in area under the log-transformed bacterial count versus time curve across all Smc isolates in static concentration time-kill assays. In the hollow fibre infection model, ATM + CZA achieved ≥3-log10 CFU/mL reduction at 24 hours from an initial ∼7.5-log10 CFU/mL inoculum. This effect was sustained over 168 hours against GG6 strain. Against the non-GG6 strain, both continuous-infusion and standard-dosing regimens showed ∼2-log10 regrowth after 72 hours, but overall suppressed resistant subpopulations more effectively than trimethoprim/sulfamethoxazole. CONCLUSIONS: Smc infections remain challenging because of intrinsic resistance mechanisms. These findings demonstrate the therapeutic potential of ATM + CZA, and support further evaluation using murine pneumonia and bacteraemia models of S. maltophilia.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Vallé Q, Sharma R, Bui NM, et al. Evaluating the antibacterial activity of ceftazidime/avibactam and aztreonam combinations against multidrug-resistant Stenotrophomonas maltophilia complex isolates in a hollow fibre infection model. Clin Microbiol Infect. 2026. PMID: 41698464. doi:10.1016/j.cmi.2026.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。